Qiagen N.V. (NASDAQ:QGEN) has received an average recommendation of “Hold” from the sixteen research firms that are covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $31.72.

QGEN has been the topic of a number of recent research reports. TheStreet upgraded Qiagen N.V. from a “c” rating to a “b” rating in a research note on Monday, June 5th. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a research note on Monday, May 29th. Barclays PLC restated a “buy” rating and set a $33.00 price objective on shares of Qiagen N.V. in a research note on Monday, May 15th. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a research note on Tuesday, May 2nd. Finally, BidaskClub lowered Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 10th.

Shares of Qiagen N.V. (QGEN) opened at 34.57 on Monday. The company has a market capitalization of $7.87 billion, a PE ratio of 96.03 and a beta of 1.15. The firm has a 50-day moving average price of $34.06 and a 200-day moving average price of $30.78. Qiagen N.V. has a 12 month low of $23.70 and a 12 month high of $35.26.

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Qiagen N.V. by 8,793.4% in the first quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock valued at $227,114,000 after buying an additional 7,751,485 shares during the last quarter. Legal & General Group Plc raised its position in shares of Qiagen N.V. by 2,651.3% in the first quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock valued at $16,690,000 after buying an additional 1,827,871 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Qiagen N.V. during the first quarter valued at about $46,480,000. Neuberger Berman Group LLC acquired a new position in shares of Qiagen N.V. during the first quarter valued at about $31,875,000. Finally, Renaissance Technologies LLC raised its position in shares of Qiagen N.V. by 182.9% in the first quarter. Renaissance Technologies LLC now owns 1,514,898 shares of the company’s stock valued at $43,890,000 after buying an additional 979,498 shares during the last quarter. Institutional investors own 61.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Qiagen N.V. (NASDAQ:QGEN) Given Average Recommendation of “Hold” by Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/24/qiagen-n-v-nasdaqqgen-given-average-recommendation-of-hold-by-analysts.html.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.